ICAN SENDS CRITICAL AND TIMELY INFORMATION TO EACH MEMBER OF ACIP AHEAD OF THEIR VOTE THAT WILL DETERMINE THE FATE OF THE J&J/JANSSEN COVID-19 VACCINE
EMERGENCY PETITION TO HALT CLINICAL TRIAL OF ASTRAZENECA AND OXFORD’S COVID-19 VACCINE UNLESS ALL ADVERSE REACTIONS ARE TRACKED IN A PLACEBO-CONTROLLED CLINICAL TRIAL
